218 related articles for article (PubMed ID: 15136792)
1. Prospects for productivity.
Booth B; Zemmel R
Nat Rev Drug Discov; 2004 May; 3(5):451-6. PubMed ID: 15136792
[No Abstract] [Full Text] [Related]
2. Drug pipeline: 3Q15.
DeFrancesco L
Nat Biotechnol; 2015 Nov; 33(11):1126. PubMed ID: 26544135
[No Abstract] [Full Text] [Related]
3. Market watch: Upcoming catalysts in Q1 2015.
Uribe A
Nat Rev Drug Discov; 2015 Jan; 14(1):9. PubMed ID: 25503330
[No Abstract] [Full Text] [Related]
4. Biopharmaceutical benchmarks--2003.
Walsh G
Nat Biotechnol; 2003 Aug; 21(8):865-70. PubMed ID: 12894198
[No Abstract] [Full Text] [Related]
5. Market watch: Upcoming market catalysts in Q4 2016.
Hansen T
Nat Rev Drug Discov; 2016 Sep; 15(10):671. PubMed ID: 27681788
[No Abstract] [Full Text] [Related]
6. A merger too far?
Wadman M
Nature; 2007 Mar; 446(7131):15. PubMed ID: 17330017
[No Abstract] [Full Text] [Related]
7. Key factors in the rising cost of new drug discovery and development.
Dickson M; Gagnon JP
Nat Rev Drug Discov; 2004 May; 3(5):417-29. PubMed ID: 15136789
[No Abstract] [Full Text] [Related]
8. Upcoming market catalysts in Q4 2019.
Ranj T
Nat Rev Drug Discov; 2019 Sep; 18(10):738. PubMed ID: 31570850
[No Abstract] [Full Text] [Related]
9. User fees to hasten FDA review.
Gershon D
Nature; 1992 Oct; 359(6396):567. PubMed ID: 1406982
[No Abstract] [Full Text] [Related]
10. Concerns raised over declining antiinfectives R&D.
Fox JL
Nat Biotechnol; 2003 Nov; 21(11):1255-6. PubMed ID: 14595340
[No Abstract] [Full Text] [Related]
11. A changing drug supply.
Nature; 2007 Feb; 445(7127):460. PubMed ID: 17268432
[No Abstract] [Full Text] [Related]
12. Market watch: upcoming market catalysts in Q4 2010.
Rosenthal J
Nat Rev Drug Discov; 2010 Oct; 9(10):755. PubMed ID: 20885399
[No Abstract] [Full Text] [Related]
13. Security market reaction to FDA fast track designations.
Anderson CW; Zhang Y
J Health Care Finance; 2010; 37(2):27-48. PubMed ID: 21294437
[TBL] [Abstract][Full Text] [Related]
14. FDA dependence on drug industry.
Lawson GW
J Natl Med Assoc; 2005 Jul; 97(7):1039-40. PubMed ID: 16080677
[No Abstract] [Full Text] [Related]
15. 2004 approvals: the demise of the blockbuster?
Frantz S
Nat Rev Drug Discov; 2005 Feb; 4(2):93-4. PubMed ID: 15756752
[No Abstract] [Full Text] [Related]
16. The drug that could have been.
Schultz S
US News World Rep; 2002 Aug; 133(7):18, 20-3. PubMed ID: 12195678
[No Abstract] [Full Text] [Related]
17. Who pays what in drug development.
Love J
Nature; 1999 Jan; 397(6716):202. PubMed ID: 9930689
[No Abstract] [Full Text] [Related]
18. Letter from the Commissioner's Office at the US FDA.
Vernon JA
Pharmacoeconomics; 2007; 25(4):267-8. PubMed ID: 17402801
[No Abstract] [Full Text] [Related]
19. The Prescription Drug User Fee Act of 1992: speeding up the drug approval process.
Bierut MB
Healthspan; 1992 Dec; 9(11):12-4. PubMed ID: 10123552
[No Abstract] [Full Text] [Related]
20. Paying for drug approvals--who's using whom?
Avorn J
N Engl J Med; 2007 Apr; 356(17):1697-700. PubMed ID: 17435083
[No Abstract] [Full Text] [Related]
[Next] [New Search]
